ENBREL Indication Expanded

Article

The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.

Related Videos
Related Content

4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Overview of Maui Derm NP+PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Overview of Maui Derm NP+PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Overview of Maui Derm NP+PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.